The TNBC subgroup in both years was similar in this study (17.2% in 2012 and 14.2% in 2022), in keeping with the findings reported in other local studies.17,18,20,29 The current authors did not see a pattern of more aggressive tumours such as HER2 enriched and TNBC subtypes. The gene discussed is ERBB2; the disease is neoplasm.